Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-142 in Idiopathic Pulmonary Fibrosis
NCT07230288Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jan 2026
- Primary completion
- Sep 2029
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 2 trial of ABBV-142 in idiopathic pulmonary fibrosis (IPF), sponsored by AbbVie Inc.. Started Jan 2026; status: recruiting.
02
Drugs
ABBV-142
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT07230288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07230288.